ETH 47
Alternative Names: ETH-47Latest Information Update: 21 Jun 2024
At a glance
- Originator ethris
- Developer Ethris
- Class Antivirals; RNA
- Mechanism of Action Immunomodulators; Interferon type III expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Respiratory tract infections
- Preclinical COVID 2019 infections; Influenza A virus infections
Most Recent Events
- 18 Jun 2024 Ethris plans a phase II trial for Viral infections
- 28 Nov 2023 Ethris plans phase-I in Respiratory tract infections (In volunteers) in United Kingdom in December 2023
- 28 Nov 2023 Medicines and Healthcare products Regulatory Agency (MHRA) approves clinical trial authorization (CTA) application for ETH 47 in Respiratory tract infections (In volunteers)